Participants 129 151 3
standard-risk patients
Participants 387 414 3
standard-risk (SR) patients
Participants 520 566 5
SR patients (localized tumors, volume <100 mL)
Participants 846 891 4
HR patients (volume >or=100 mL or metastases)
Participants 1391 1399 3
SR group
Participants 2052 2063 3
SR patients
Participants 2111 2122 3
HR patients
